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 Abstract 
 
Human O
6
-alkylguanine-DNA alkyltransferase (hAGT) is a DNA repair protein that 
reverses the effects of alkylating agents by removing DNA adducts from the O
6
 position 
of guanine. Here we developed a real-time fluorescence hAGT activity assay that is 
based on the detection of conformational changes of the thrombin-binding aptamer 
(TBA). The quadruplex structure of TBA is disrupted when a central guanine is 
replaced by an O
6
-methyl-guanine. The sequence also contains a fluorophore 
(fluorescein) and a quencher (dabsyl) attached to the opposite ends. In the unfolded 
structure, the fluorophore and the quencher are separated. When hAGT removes the 
methyl group from the central guanine of TBA, it folds back immediately into its 
quadruplex structure. Consequently, the fluorophore and the quencher come into close 
proximity, thereby resulting in decreased fluorescence intensity. Here we developed a 
new method to quantify the hAGT without using radioactivity. This new fluorescence 
resonance energy transfer assay has been designed to detect the conformational change 
of TBA that is induced by the removal of the O
6
-methyl group. 
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 Introduction 
Alkylating agents are chemotherapeutic anticancer drugs that produce their 
cytotoxic effect by generating adducts at multiple sites in DNA [1]. A subset of 
alkylating agents, which includes nitrosoureas and temozolamide, has a preference for 
alkylating guanine at the O
6
 position, which is the most relevant in terms of mutagenesis 
and carcinogenesis [2-9]. In particular, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) 
attacks initially at the O
6
 guanine position, causing its rearrangement in a cyclic 
intermediate thus giving rise to N
1
,O
6
-ethanoguanine [10]. Finally, a cross-link with the 
opposite cytosine is formed and, as a consequence, DNA replication is blocked, 
producing G2/M arrest [11]. In addition to the well known side effects and limitations 
of chemotherapeutic agents, these substances also present problems of acquired tumor 
resistance. In particular, the DNA-repair human O
6
-alkylguanine DNA alkyltransferase 
(hAGT or MGMT) is responsible for removing alkyl adducts from the O
6
 position of 
guanines, thereby blocking the cytotoxic effects of the alkylating agents and making a 
crucial contribution to the resistance mechanism [12-14]. It is well established that 
tumor cells show greater expression of this protein than healthy cells. Thus this 
increased expression appears to be predictive of a poor response to chemotherapeutic 
drugs. This effect has been observed in a large number of cancers, ranging from colon 
cancer, lung tumors, breast cancer, pancreatic tumors, non-Hodgkin’s lymphoma, 
myeloma and glioblastoma multiforme, among others [15-17]. In addition methylation 
of the hAGT promoter and consequently the complete depletion of hAGT has been 
associated with longer survival in patients with gliomas undergoing combined radiation-
chemotherapy treatment [18-19]. Therefore, pharmacological inhibition of hAGT has 
the potential to enhance the cytotoxicity of a diverse range of anticancer agents [20]. 
hAGT is a 22-kDa (207 AA) DNA-binding protein that contains a highly 
conserved internal cysteine, which acts as the acceptor site for alkyl groups. The S-
alkyl-Cys formed is not regenerated and the protein, which behaves as a suicidal 
enzyme, inactivates itself in the dealkylation process [21-22]. This single-turnover of 
hAGT renders it vulnerable to inactivation. On the basis of this observation, intense 
research effort has been devoted to the identification of small molecules capable of 
inhibiting hAGT activity and significantly enhancing the cytotoxic effect of BCNU in 
prostate, breast, colon and lung tumor cells [20].  
 Several methods are available to characterize the mechanism of action of hAGT, 
and its activity. Moreover, they also have the capacity to evaluate the capacity of small 
molecules to inhibit hAGT. Most of these methods are based on radioactivity assays 
while others are based on multiple-step enzymatic reactions [23-26].  
G-quadruplexes are a family of four-stranded DNA structures stabilized by the 
stacking of guanine tetrads, in which four planar guanines form a cyclic array of 
hydrogen bonds [27]. These G-rich regions are connected by lateral, central or diagonal 
loops of diverse sizes and composition that form base-pairing alignments, which in turn 
stack with the terminal G-tetrads, thus further stabilizing G-quadruplex structures [28]. 
Another key element in G-quadruplex formation is the presence of monovalent cations, 
which stabilize the negative electrostatic potential created by the guanine O
6
 oxygen 
atoms within the quadruplex core [29-30]. However, most divalent cations have the 
capacity to induce the dissociation of G-quadruplex structures [31]. Finally, 
modifications in the base composition of the tetrads are poorly tolerated by these 
structures. As an example, inosine [32] and O
6
-methylguanine [33], both non-natural 
bases can form a smaller number of hydrogen bonds and thus destabilize the G-
quadruplex.  
Given the potential relevance of hAGT as a prognostic marker of cancer and as a 
therapeutic target, and that its substrate O
6
-methylguanine disrupts the formation of G-
quadruplex structures [33], here we developed a new fluorescence activity assay for 
hAGT. For this purpose, we selected the thrombin-binding aptamer (TBA) as our G-
quadruplex model. TBA is a well known 15 mer that adopts a chair-like structure 
consisting of two G-tetrads connected by two lateral TT loops and a central TGT loop 
[34]. The modification of its sequence in positions 5 or 6 by replacing a guanine of the 
tetrad for an O
6
-methylguanine disrupts folding, leaving it in an extended conformation. 
Giving that the two conformations bring the two ends of TBA together or taken them 
further apart, our working hypothesis was that the incorporation of fluorescence probes 
result in a measurable change in intensity. The final aim of this fluorescence assay was 
to measure the DNA repair activity of hAGT, and thus facilitate the search for new and 
more potent inhibitors which enhance chemotherapeutic drugs. Although several 
methods have been described to quantify hAGT activity [23-26], none of them use the 
conformational change of G-quadruplex for this purpose. Here we describe the 
development of a straightforward, rapid, one-step fluorescence resonance energy 
transfer (FRET) assay. 
  
Materials and Methods 
 
Abbreviations. BME: 2-mercaptoethanol; Dabsyl: N-4’-sulfonyl-4-(dimethylamino)-
azobencene)-3-aminopropyl; dmf: dimethylformamidino group; DTT: dithiothreitol; 
EDTA: ethylenediaminetetraacetic acid; FAM: fluoresceine; AGT: O
6
-alkylguanine-
DNA alkyltransferase; hAGT: human AGT; HPLC: high performance liquid 
chromatography; IPTG: Isopropyl -D-1-thiogalactopyranoside; MB: Molecular 
Beacon; O
6
-MeG: O
6
-methylguanine; TBA: thrombin-binding aptamer; cTBA: 
complementary TBA; TEAA: triethylammonium acetate; TFA: trifluoroacetic acid; 
Tris: Tris(hydroxymethyl)aminomethane; Tm: melting temperature and UV: Ultraviolet. 
 
Chemicals  
5’-Fluorescein CE phosphoramidite (6-FAM), 3’-Dabsyl CPG, O6-methylguanine (O6-
MeG) and G
dmf
 phosphoramidites were purchased from Link technologies (UK) and 
Glen Research (USA). O
6
-methylguanine was protected with the isobutyryl group [35]. 
Standard phosphoramidites and ancillary reagents were purchased from Applied 
Biosystems (Europe).  
The matrices for MALDI-TOF experiments were 2’,4’,6’-trihydroxiacetophenone 
monohydrate (THAP) and ammonium citrate dibasic. 
Solvents for chromatographic analysis were prepared using triethylamine, acetic acid 
and acetonitrile as mobile phase. All other chemicals were of analytical reagent grade 
and were used as supplied. Ultrapure water (Millipore, USA) was used in all 
experiments. 
 
Instrumentation. 
Semi-preparative reverse phase (RP) HPLC was performed on a Waters 
chromatography system using Nucleosil semi-preparative 120 C18 (250x8mm) columns. 
Analytical RP-HPLC was performed using an XBridge OST C18 2.5 μm column and a 
Nucleosil Analytical column 120 C18 (250x4mm). Oligonucleotides were detected by 
UV absorption at 260 nm. Mass spectra were recorded on a MALDI Voyager DE
TM
 RP 
time-of-flight (TOF) spectrometer (Applied Biosystems, USA) with a nitrogen laser at 
337 nm using a 3-ns pulse. Fluorometric measurements were performed on a 
 spectrofluorometer Multi-Detection microplate reader Biotek FLx800 and a Jasco 
FP6200. Molecular absorption spectra between 220 and 550 nm were recorded with a 
Jasco V650 spectrophotometer. The temperature was controlled with a Jasco ETC 272T 
Peltier device. Hellma quartz cuvettes (0.5 and 1.0 cm path length, 500 or 1000 μl 
volume) were used.  
 
Oligonucleotide synthesis. 
Oligonucleotide sequences (shown in Table 1) were synthesized on an ABI 3400 DNA 
Synthesizer (Applied Biosystems, USA) using a 200-nmol scale synthesis and following 
the standard protocols. We used dimethylformamidino-protected guanine G
dmf
 
phosphoramidite for all the syntheses. 5’-Fluorescein CE phosphoramidite (6-FAM), 
O
6
-methylguanine (O
6
-MeG) and G
dmf
 phosphoramidites were from commercial sources. 
The isobutyryl group was used to protect the amino group of O
6
-MeG [35]. The 
quencher group was introduced at the 3’ end using the controlled pore glass 
functionalized with a 3’-Dabsyl derivative CPG. O6-MeG-containing oligonucleotides 
were deblocked using concentrated aqueous ammonia overnight at room temperature 
following the manufacturer’s instructions. The resulting products were desalted by 
Sephadex G-25 (NAP-10, GE Healtcare, USA) and purified by reversed-phase HPLC 
using Nucleosil columns. The yields and purities obtained for the products were around 
85% for 5-O
6
-MeG-TBA and 6-O
6
-MeG-TBA, and > 98% for the rest of the sequences. 
The length and homogeneity of the oligonucleotides were checked by MALDI-TOF. 5-
O
6
-MeG-TBA [M]=4731.7 (expected 4737.8), 6-O
6
-MeG-TBA [M]=4729.9 (expected 
4737.8), MB-5-O
6
-MeG-TBA [M]=5828.49 (expected 5826.0), MB-6-O
6
-MeG-TBA 
[M]=5826.80 (expected 5826.0). 
The DNA-strand concentration was determined by absorbance measurements (260 nm) 
by calculating extinction coefficients. Oligonucleotide samples were kept at 4 ºC until 
further use. Double-stranded O
6
-MeG-TBA was formed by annealing equimolar 
concentrations of complementary oligonucleotide strands at 72 ºC for 5 min and then 
allowed to slowly cool to room temperature. 
 
Melting temperature studies.  
Melting curves were measured by monitoring the absorbance hyperchromicity at 295 
and 495 nm in a JASCO V650 spectrophotometer equipped with a Peltier temperature-
controlling unit. UV/Vis absorption spectra were recorded at 1ºC/min intervals, with a 
 1-min equilibration time at each temperature; the sample was heated over the range 20-
80 ºC. The buffer solutions used were 10 mM sodium cacodylate pH 7.0 and 100 mM 
KCl. Sample concentration was around 4 μM. Each sample was allowed to equilibrate 
at the initial temperature without any external control of temperature for 5 min before 
the melting experiment began. The melting temperatures (Tm) are the average value of 
at least one pair of Tm experiments. 
 
CD spectra. 
Samples were prepared as described for the melting experiments by UV spectroscopy. 
Measurements were conducted in 10 mM sodium cacodylate pH 7.0 and 100 mM KCl. 
Sample concentration was between 1-4 μM. The CD spectra were recorded on a Jasco J-
810 spectropolarimeter attached to a Julabo F/25HD circulating water bath in 1 cm 
path-length quartz cylindrical cells. Spectra were recorded at room temperature using a 
100 nm/min scan rate, a spectral band width of 1 nm and a time constant of 4 s. All the 
spectra were corrected with the buffer blank and plotted using Origin software.  
 
Human recombinant hAGT protein.  
Full-length hAGT was overexpressed and purified as previously described [36]. Briefly, 
hAGT protein cloned in the pet-21a(+) (Novagen) vector was expressed in the E. coli 
strain Rosetta. Once the culture reached an OD600 value of 0.98, hAGT was induced by 
adding 1 mM IPTG (Sigma) and left for 4 h at 30 °C. The pellet from a 1-L culture was 
disrupted by sonication and centrifuged. The supernatant was filtered, loaded into a 
HiTrap
TM
 FF column (GE Healthcare) with buffer 350 mM NaCl, 20 mM Tris pH 8, 20 
mM imidazole, and 1 mM BME, and then eluted with an imidazole (Fluka) gradient up 
to 500 mM in the same buffer. Finally, the protein was loaded into a Superdex 75 16/60 
column (GE Healthcare) with the following buffer: 200 mM NaCl (Merck), 20 mM Tris 
pH 8.0 (Merck), 10 mM DTT (Sigma) and 0.1 mM EDTA (Sigma). The protein was 
concentrated to 2 mg/ml in this buffer and kept at -20 °C in the presence of 40 % 
glycerol. The same protocol was used for the purification of the inactive mutant hAGT-
C145S, cloned in the pet-28a (+) vector (Novagen) and expressed in the E. coli strain 
BL21.  
 
HPLC hAGT assay. 
 Assays were conducted using double-stranded 5-O
6
-MeG and 6-O
6
-MeG TBA paired 
with TBA complementary sequence or using single-stranded 5-O
6
-MeG and 6-O
6
-MeG 
TBA. 
In order to measure the dealkylation of O
6
-MeG, 50 pmol of the O
6
-MeG-TBA 
substrates were incubated with a range of concentration of hAGT (16 nM to 1.6 M)  to 
a final volume of 120 l in a reaction buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM 
DTT, 5 mM EDTA). Several incubation times were tested (30, 60, 90, 120, 360 and 
1440 min) at 37 ºC and the reaction was stopped by heating the samples at 72 ºC for 5 
min. The reaction products were analyzed by HPLC on a Nucleosil analytical column at 
60 ºC or room temperature, depending on the substrates used in the experiment (double- 
or single-stranded TBA). The HPLC flow rate was 1 ml/min, and a gradient of 10–40% 
acetonitrile for 20 min was used. 
 
Fluorescence assay for hAGT activity. 
The fluorescence assay was performed in a Multi-Detection Microplate Reader Biotek 
FLx800 in optical 96-well Optical btm reaction plates (Nunc, USA). Full-length hAGT 
recombinant protein (207 amino acids) was used for the assay and the hAGT-C145S 
inactive mutant was used as a negative control. The reaction was performed in a total 
volume of 50 μl in each well, incubating increasing concentrations of hAGT (5, 10, 20, 
40, 60, 80 nM) enzyme in reaction buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM 
DTT, 5 mM EDTA, 20 mM KCl). The assay of hAGT was then initiated by the addition 
of 5 μl of different concentrations (5, 10, 25 and 50 nM) of fluorescently labelled MB-
O
6
-MeG-TBA substrate and this solution was then placed in a microplate reader system. 
Fluorescence was measured every minute for 20 min or 40 min at excitation and 
emission wavelengths of 485 and 535 nm, respectively. Averages over three readings 
were taken for each condition tested. Each experiment was performed in triplicate. 
 
Results and Discussion 
The aim of this study was to develop a real-time hAGT activity assay based on the 
detection of differences between extended and folded conformations of TBA. Our 
working hypothesis was that the quadruplex structure of TBA is disrupted when a 
central guanine is replaced by an O
6
-methylguanine. The TBA sequence also contains a 
fluorophore and a quencher group attached to 5’ or 3’ end respectively. In the presence 
 of O
6
-methylguanine, methylated TBA unfolds and the fluorophore and the quencher 
become physically separated beyond the Förster distance. When the repair protein 
hAGT is added to the methylated aptamer, the enzyme removes the methyl group from 
the mutated guanine, thus allowing TBA to fold back into its chair-like conformation. 
As a result, the quencher comes closer to the fluorophore and blocks its fluorescence, as 
illustrated in Figure 1. This loss of fluorescence is quantified as a direct measurement of 
hAGT activity. 
 
 
Synthesis of modified G-quadruplex sequences. 
The G-quadruplex sequences used in this study are shown in Table 1. Oligonucleotide 
synthesis was performed by the solid-phase 2’-cyanoethyl-phosphoramidite method 
[37]. Ammonia treatment was performed at room temperature overnight to minimize 
decomposition of O
6
-methylguanine. For the same reason, the dimethylformamidino 
group was selected for the protection of 2’-deoxyguanosine [38]. The sequences were 
characterized by HPLC and mass spectrometry, which provided the expected molecular 
weights. The yields of the isolated molecular beacon oligonucleotides after HPLC 
purification and desalting were in the range of those obtained for unmodified 
oligonucleotides. 
 
Thermal stability of methylguanine-modified TBA. 
In order to induce the unfolding of the quadruplex structure of TBA, we introduced an 
O
6
-methyl-guanine at position 5 or 6 of TBA. Melting curves of the modified sequences 
were performed by UV spectroscopy and compared with the unmodified sequence. 
These experiments were carried out at pH 7 in buffer containing 10 mM sodium 
cacodylate and 100 mM KCl, which is predicted to stabilize G-quadruplexes structures. 
We did not observe a melting temperature at 295 nm for 5-O
6
-MeG-TBA or 6-O
6
-MeG-
TBA and the corresponding molecular beacons (see Figures S1-S4 in supplementary 
data). The absence of this transition is consistent with the disruption of the quadruplex 
structure. These results contrast with the melting temperature of native TBA (Tm 48 ºC) 
and MB-TBA (Tm 46 ºC). Moreover, circular dicroism of methylated-TBA derivatives 
did not show the presence of the maximum at 295 nm, which is characteristic of the 
antiparallel quadruplex of TBA (Figure 2 and Figure S5). These results confirmed that 
 methylation of guanine in either of the two positions of the TBA sequence prevents the 
formation of the chair structure. This observation confirms our working hypothesis. 
Given that the DNA repair activity exerted by hAGT is higher in double-stranded DNA 
than single-stranded DNA [39], we studied the stability and the quadruplex formation of 
elongated self-complementary TBA derivatives (see Table 1). We designed several 
TBA oligonucleotides elongated in their 3’ end with a subset of self-complementary 
sequences of diverse sizes. The purpose of these elongations was to check whether the 
extended sequences have the capacity to form a double strand helix of different lengths 
and strengths with themselves without disrupting the chair-like structure. For 6-HP-
TBA and 9-HP-TBA, we found that the corresponding Tm at 260 nm were 63 ºC and 
71.8 ºC respectively. This observation confirms our hypothesis of a double helix 
structure that increases in strength as the sequence length increases. However, we did 
not detect a melting temperature of these two sequences at 295 nm. The absence of a 
transition at 295 nm is consistent with the absence of an antiparallel quadruplex 
structure. In contrast, 3-HP-TBA, corresponding to an overhang of only 3 nucleotides, 
gave a melting temperature of 46 ºC at 295 nm, which is slightly but similar to that 
obtained for natural TBA. This result indicates that 3-HP-TBA forms an antiparallel 
quadruplex instead of a duplex because the overhang is too short to break the chair-like 
structure. Circular dichroism confirms the quadruplex structure of 3-HP-TBA and the 
absence of quadruplex structure in 6-HP-TBA and 9-HP-TBA (Figure S6). Models of 
all these structures are shown in Figure 3.  
 
HPLC analysis of DNA repair activity of hAGT. 
In order to observe the capacity of hAGT to remove alkyl groups from single-stranded 
oligonucleotides, we performed several assays to determine the optimal conditions of 
the reaction. 
For this purpose, the full-length hAGT was first over-expressed and purified as 
described previously [36]. Increasing concentrations of the protein were incubated with 
double-stranded 5-O
6
-MeG and 6-O
6
-MeG TBA, annealed with its complementary 
sequence. Figure 4A shows the HPLC profile of the final product of the reaction with 
double-stranded 5-O
6
-MeG-TBA. In order to separate the two strands of the TBA 
substrate (Figure 4A top right panel), HPLC analyses were done at 60 ºC. After 
incubation with hAGT we detected a peak with a shorter retention time, which 
corresponds to the restored TBA sequence caused by the removal of the methyl group. 
 We obtained the same results when we used double-stranded 6-O
6
-MeG-TBA as a 
substrate (data not shown). As expected, hAGT activity was not affected by the position 
of the alkyl group within the sequence. We then tested hAGT activity over single-
stranded methylated TBA in the previously optimized conditions and obtained similar 
results to those shown in Figure 4B. The top right panel shows the HPLC chromatogram 
in the absence of hAGT. In this case, the HPLC analyses were performed at room 
temperature because the substrate was single-stranded TBA. Our results confirmed that 
hAGT has the capacity to remove methyl groups from single- or double-stranded TBA 
with the same efficacy. Therefore, we selected single-stranded TBA as substrate for the 
development of our fluorescence assay.  
 
Fluorescence hAGT activity assay. 
On the basis of the results obtained in the melting temperature and the HPLC 
experiments, we tested the effectiveness of our proposed model to the DNA repair 
activity of hAGT by means of fluorescence. First of all, we determined the minimum 
amount of TBA required to achieve a detectable and reliable difference in intensity 
compared to the background. As expected, the negative control natural TBA quadruplex 
gave low background fluorescence, because of the proximity of the fluorophore and the 
quencher groups in the chair-like structure (Figure 5A). Although the fluorescence of 
MB-TBA was low, this fluorescence was subtracted from the fluorescence value in each 
experiment. The concentration of 5 nM of fluorescently labelled MB-O
6
-MeG-TBA was 
considered the optimal concentration as the fluorescence signal was intense and only a 
small amount of hAGT protein was required to achieve a substantial decrease in 
fluorescence in 20-40 min. In the optimal conditions, the presence of hAGT produced a 
remarkable decrease in fluorescence intensity, caused by the demethylation of the O
6
 
position of guanines, thereby allowing the TBA to form its typical quadruplex structure, 
which brings together the fluorophore and the quencher groups, as occurred in the 
negative control. The rate of decrease in fluorescence intensity correlated directly with 
the amount of hAGT in the reaction mixture (Figure 5B). Moreover, the inactive mutant 
hAGT-C145S did not exhibit any decrease in fluorescence (Figure 5A). This result was 
expected because of the incapacity of this mutated protein to repair the modified TBA. 
Figure 5B shows the fluorescence intensities for the real time hAGT assay. All these 
observations are consistent with the hypothesis and design of our FRET method. 
 
 CONCLUSION 
Although radioactivity has been widely used in the search of potential inhibitors of 
hAGT [23-24], this technique does not allow real-time data acquisition and, in addition, 
requires radioactive materials. Here, we developed a sensitive fluorescence method that 
allows the quantification of hAGT activity in a single step and in a straightforward 
manner. Although another fluorescence method has already been developed for this 
purpose [25], it requires the addition of a restriction enzyme, followed by the addition 
of an exonuclease after the hAGT activity reaction. Consequently, although it is a real-
time assay, a three-step reaction is required before observing an increase in fluorescence. 
In contrast, in our assay, a change in fluorescence is detected in a single step 
(homogeneous), and this method does not depend on the activity of two additional 
enzymes.  
Our assay is based on the detection of conformational changes of TBA in the presence 
or absence of O
6
-methylguanines in its structure. The quadruplex structure of TBA is 
disrupted when a central guanine is replaced by an O
6
-methylguanine. Fluorophore 
groups can be added to the modified sequence in order to detect the conformational 
changes by fluorescence. The variation in fluorescence can be quantified as a direct 
measurement of hAGT activity. In addition, this technique requires lower amounts of 
substrate and does not call for the use of radioactive materials. Furthermore, this method 
can be easily transferred to a high throughput experiment for the evaluation of small 
molecules as potential hAGT inhibitors [36]. Research in this direction is currently 
underway in the laboratory. 
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 FIGURE CAPTIONS. 
 
Figure 1. Scheme of fluorescence-based hAGT assay. The substrate is the thrombin-
binding aptamer modified by an O
6
-methylguanine (Me) in extended conformation, 
with a fluorophore and quencher in the opposite ends of the sequence. The refold of the 
G-quadruplex structure of TBA is dependent on the removal of the methyl adduct by 
alkyl-guanine-DNA-O
6
-alkyltransferase (hAGT). This repair moves the quencher and 
the fluorophore molecules in close proximity and blocks fluorescence.  
 
Figure 2. CD spectra of MB-TBA and MB-5-O
6
-MeG-TBA at 25 ºC. Buffer 
conditions: 10 mM sodium cacodylate pH 7.0 and 100 mM KCl, sample concentration 1 
M. 
 
Figure 3. Schematic representation of the structure of several derivatives of thrombin 
binding aptamers (TBAs) prepared in this study. TBA sequence is shown in black, and 
T4 loop with different sizes of the complementary sequences are shown in red. A) 
Native TBA; B) TBA-hairpin containing three overhanging complementary nucleotides 
(3-HP-TBA); C) TBA-hairpin containing six overhanging complementary nucleotides 
(6-HP-TBA); D) TBA-hairpin containing nine overhanging complementary nucleotides 
(9-HP-TBA). Between 3-6 complementary nucleotides are required to disrupt the 
intramolecular quadruplex to form an intramolecular duplex.  
 
Figure 4. HPLC analysis of hAGT activity over double- and single-stranded TBA 
before and after incubation with hAGT. A) Repair of double-stranded 5-O
6
-MeG-TBA 
by hAGT. The peak labelled as cTBA corresponds to the complementary sequence of 5-
O
6
-MeG-TBA. The top right panel shows HPLC chromatogram in absence of hAGT. 
The gradient was from 10–40% acetonitrile for 20 min at 60 ºC. B) Repair of single- 
stranded 5-O
6
-MeG-TBA by hAGT. The inserted panel shows HPLC chromatogram in 
the absence of hAGT. Gradient used: 10–40% acetonitrile, 20 min at room temperature. 
 
Figure 5. Fluorescence intensity of the real-time hAGT assay, measured at excitation 
and emission wavelengths of 485 nm and 535 respectively. A) Illustration of the 
different controls with 5 nM MB-5-O
6
-MeG-TBA: 1) Positive control of MB-5-O
6
-
MeG-TBA in the absence of hAGT; 2) Intensity in presence of the inactive mutant 
hAGT-C145S; 3) Decrease in fluorescence when adding 40 nM active hAGT; and 4) 
 basal fluorescence of 5 nM of MB-TBA. B) Decrease in intensity caused by the activity 
of hAGT at a range of concentrations (0, 20, 40 and 60 nM), in all of them the basal 
fluorescence of MB-TBA was subtracted. 
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Table 1. Sequences of TBA oligonucleotide derivatives used in the development of the 
hAGT fluorescence assay. 
Me
G represents O
6
-methylguanine. MB represents the 
fluorophore group (FAM), labelled in the 5’ end, and the quencher group (Dabsyl), 
labelled in the 3’ end of the sequence. 
 
 
Abbreviation Sequence 
TBA 5´-GGT TGG TGT GGT TGG-3´ 
5-O
6
-MeG-TBA 5´-GGT T
Me
GG TGT GGT TGG-3´ 
6-O
6
-MeG-TBA 5´-GGT TG
 Me
GTGT GGT TGG-3´ 
C-TBA 5´-CCA ACC ACA CCA ACC-3´ 
MB-TBA 5´-FAM-GGT TGG TGT GGT TGG-Dabsyl-3´ 
MB-5-O
6
-MeG-TBA 5´-FAM-GGT T 
Me
GG TGT GGT TGG- Dabsyl-3´ 
MB-6-O
6
-MeG-TBA 5´-FAM-GGT TG 
Me
G TGT GGT TGG- Dabsyl-3´ 
3-HP-TBA 5´- A CCT TTT GGT TGG TGT GGT TGG-3´ 
6-HP-TBA 5´- C CAA CCT TTT GGT TGG TGT GGT TGG-3´ 
9-HP-TBA 5´- A CAC CAA CCT TTT GGT TGG TGT GGT TGG-3´ 
 
 
